Tumor stage analysis showed that the P16 promoter was methylated only in stage T2 tumors (8% vs. 0%; p = 0.041), while promoter hypermethylation of RUNX3 was significantly more common in cases with affected nodes (52% vs. 31%; p = 0.032). This evidence concerns the gene RUNX3 and neoplasm.